Author

S. Tilleux

OpenAlex ID: A5117508317

Long-term Safety and Efficacy Data With Inhaled Pirfenidone (AP01) in the Atlas Open-label Extension Study Up to 240 Weeks

2025 · T.J. Corte, S. Tilleux, et al. · American Journal of Respiratory and Critical Care Medicine · 1

POS0005 Inhaled Pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design

2025 · O. Distler, C. Reisner, et al. · Annals of the Rheumatic Diseases

Works count: 2

Citation count: 1

H-index: 1

I10-index: